LYMPHOMAS

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.

The FDA has granted a breakthrough therapy designation to the brentuximab vedotin for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.&nbsp;<br /> &nbsp;

Studies testing immune checkpoint inhibitors in combination with other agents for the treatment of both Hodgkin and non-Hodgkin lymphoma are garnering attention among researchers.

Castleman Disease with Corey Casper, MD

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

Two oncologists from Emory University School of Medicine faced off to determine if molecular markers should play a role in the treatment of subgroups of patients with diffuse large B-cell lymphoma.&nbsp;

According to findings from a multicenter randomized trial, chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival (PFS) compared with involved-field radiotherapy alone (IFRT).

Goals of &quot;Project Impact: A Campaign to Defeat Pediatric Brain Tumors&quot;&nbsp;include improving clinical outcomes for pediatric brain tumor patients and informing the development of the first-ever standard of care for treating pediatric high-grade gliomas.

As therapeutic approaches with more efficacy and less toxicity are still highly needed, researchers are currently working to identify new targets in the MB field.

The management of medulloblastoma, the most common malignant brain cancer in children, has not changed in decades but breakthroughs are on the horizon.

Data from the phase I HD7 through HD11 trials proves promising enough to move on to phase II.